Clinical Research Informer

iPSC Manufacturing Summit

pharmaphorum

APRIL 25, 2022

This forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products, with in depth case studies aimed to develop optimal differentiation, cryopreservation, and analytical protocol to enhance process development to ensure it is robust, rapid and repeatable. Hear from: Fate Therapeutics.

Manufacturing

Manufacturing Gene Editing Branding Production

ValiRx appoints interim CSO to drive drug discovery efforts

Drug Discovery World

OCTOBER 4, 2022

Life science company ValiRx has appointed Dr Cathy Tralau-Stewart as its interim Chief Scientific Officer (CSO) to help bolster its drug discovery and therapeutic expertise. ValiRx is focused on early-stage cancer therapeutics and women’s health. .

Drugs

Drugs Life Science Development Medicine

Target validation in psychiatry: addressing unmet therapeutic needs

Drug Discovery World

NOVEMBER 7, 2022

EP : The Psychiatry Consortium, launched in 2019, is a strategic collaboration of leading medical research charities and pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of people living with mental health conditions. .

Packaging

Packaging Packaging Drugs Clinical Trials

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

The Pharma Data

NOVEMBER 1, 2020

CAMBRIDGE, England–( BUSINESS WIRE )– Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect. – ENDS – NOTES TO EDITORS: About Mission Therapeutics.

Clinical Research

Clinical Research Medicine Development Research

The DDW Podcast: 2023 in review

Drug Discovery World

DECEMBER 27, 2023

Dr Pierre Eftehkari, Chief Scientific Officer of Inoviem Scientific, joined the podcast series to share his insight into the future of drug development, leaning on his in-depth understanding of the pharmaceutical industry and its needs. The final episode of the year was with Isaac Klein, Chief Scientific Officer of Dewpoint Therapeutics.

Clinical Trials

Clinical Trials Clinical Trials Drugs Development

llergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting

The Pharma Data

JULY 21, 2021

vice president, global therapeutic area head, eye care, AbbVie. This allows for an increased depth of focus without compromising distance vision. Robinson , M.D., DURYSTA Consumer Indications and Usage and Important Safety Information. For more information about AbbVie, please visit us at www.abbvie.com.

Production

Production Doctors Doctor Medicine

Sandoz spin-off continues Novartis’ focus on innovation; $22bn purchase rumoured

Pharmaceutical Technology

SEPTEMBER 26, 2022

Novartis (Basel, Switzerland) has announced plans for a spin-off of its underperforming subsidiary, Sandoz, and will focus on innovative treatment approaches for haematology, solid tumours, immunology, neuroscience and cardiovascular-related diseases.

Manufacturing

Manufacturing Drugs Branding Sales

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

SEPTEMBER 1, 2020

Gaining insight into long-term therapeutic outcomes can enable clinicians to identify the most appropriate treatment approach for their multiple sclerosis patients. The mechanism by which Zeposia exerts therapeutic effects in multiple sclerosis is unknown but may involve the reduction of lymphocyte migration into the central nervous system.

Trials

Trials Clinical Trials Clinical Trials Vaccination

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine. For example, Ocrevus will be challenged by Novartis’ Kesimpta (ofatumumab) and TG Therapeutics’ Briumvi (ublituximab). But all three drugs have new competitors.

Sales

Sales Manufacturing FDA Approval Life Science

CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

The Pharma Data

MAY 27, 2022

Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Res), EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited. “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival.

Antibody

Antibody Medicine Nurses Licensing

Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS

The Pharma Data

OCTOBER 28, 2020

An adverse effect on revenue has been observed in some of our therapeutic areas, such as Neuroscience, for reasons such as patients visiting their medical care providers less frequently for non-life-threatening and chronic diseases. Neuroscience Neuroscience with JPY 207.8 billion in aggregate, delivered a 15.4%

Sales

Sales Production Engineer Development

Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting

The Pharma Data

APRIL 27, 2021

vice president, global therapeutic area head, eye care, AbbVie. The proposed mechanism of action of AGN-190584 is through contraction of the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near and intermediate visual acuity while maintaining some pupillary response to light. Robinson , M.D.,

Research

Research Drug Delivery Systems Drug Delivery Production

CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)

The Pharma Data

JUNE 18, 2021

The depth of response achieved with this regimen is reflected in the 30-month progression-free survival (PFS) rate of ~95% across all treated patients, including the subset receiving placebo after the fixed-duration treatment. For more information about AbbVie, please visit us at www.abbvie.com.

Medicine

Medicine Production FDA Approval Trials

Clinical Research Informer

iPSC Manufacturing Summit

ValiRx appoints interim CSO to drive drug discovery efforts

Trending Sources

Target validation in psychiatry: addressing unmet therapeutic needs

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

The DDW Podcast: 2023 in review

llergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting

Sandoz spin-off continues Novartis’ focus on innovation; $22bn purchase rumoured

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS

Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting

CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)

Stay Connected